IDEX Reports Strong Q1 Results, Raises Full-Year Guidance on Organic Sales & EPS Momentum
IEX sits 37% above its 52-week low of $157.25.
Summary
IDEX Corporation announced robust first-quarter results, exceeding expectations with strong sales and EPS growth, and subsequently raised its full-year organic sales and adjusted EPS guidance.
Key Events · Earnings and Guidance · IEX
-
Strong First Quarter Financial Performance
IDEX reported Q1 2026 sales of $887 million, an increase of 9% on a reported basis and 5% organically. Reported diluted EPS rose 28% to $1.61, and adjusted diluted EPS increased 14% to $2.00. Record orders reached $988 million, up 13% reported and 10% organically.
-
Full-Year Guidance Raised
The company raised its full-year 2026 organic sales growth projection to 3% to 4%, up from previous guidance of 1% to 2%. Full-year adjusted diluted EPS guidance was also increased to a range of $8.35 to $8.55, from the prior $8.15 to $8.35.
-
Continued Shareholder Returns
IDEX returned capital to shareholders through $76 million in share repurchases during the quarter, continuing the program detailed in the 2026-02-19 10-K filing, and paid $53 million in dividends.
-
Health & Science Technologies Segment Leads Growth
The Health & Science Technologies segment was a key driver, with net sales increasing 17% and organic sales up 11%, primarily due to AI-driven demand for data center power and semiconductor markets, as well as strength in space and defense.
Analysis · IEX · Technology
IDEX Corporation delivered robust first-quarter results, surpassing expectations with significant growth in sales, EPS, and orders. The company's decision to raise its full-year organic sales and adjusted EPS guidance signals strong operational momentum and management confidence, particularly driven by performance in the Health & Science Technologies segment. This positive update, occurring while the stock trades near its 52-week high, reinforces the company's strong market position and execution. Additionally, the continued share repurchase activity demonstrates a commitment to returning capital to shareholders, further enhancing investor sentiment.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1052 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IEX was trading at $215.06 on NYSE in the Technology sector, with a market capitalization of approximately $15.2B. The 52-week trading range was $157.25 to $217.16. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.